611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Men's Health
Resources
Basic InformationLatest News
Eating More Veggies Won't Stop Prostate Cancer: StudyFish Oil Supplements Might Help Men Become DadsAI Might Help Spot, Evaluate Prostate CancerWhat Works Best to Help Men With Overactive Bladder?'Less Is More' When it Comes to Testicular Cancer Chemo, Study SuggestsMale Fertility Supplements Fail to DeliverTestosterone Supplements Won't Help Most Men, Doctors' Group SaysCould Baldness Become 'Optional'? New Research May Give Men HopeAHA News: Erectile Dysfunction May Up the Odds for Irregular HeartbeatMuscle in Middle Age Might Help Men's Hearts LaterTestosterone Supplements Double Men's Odds for Blood Clots: StudyBeyonce's Dad Puts Spotlight on Male Breast CancerFrequent Male Pot Use Linked to Early MiscarriagesUsing Opioids After Vasectomy May Trigger Persistent Use: StudyGene-Based Therapy Helps Fight Advanced Prostate CancerLink Seen Between Infertility, Prostate CancerHigh-Dose Radiation a Game Changer in Fighting Deadly Prostate CancerAt-Risk Men May Also Benefit From Regular MammogramsDoubt Over Long-Term Use of Hormone Rx for Recurrent Prostate CancerWhat Is Your Risk for Prostate Cancer?For Men, Living Alone May Mean Poorer Control of Blood-Thinning MedsHormone Therapy for Prostate Cancer Might Harm the Heart: StudyAHA News: Common Prostate Cancer Treatment May Increase Risk of Fatal Heart ConditionHealth Cautions for Young Male AthletesOverweight Men May Feel Stigmatized, TooTestosterone Therapy May Threaten the HeartPlastic Surgery Pays Off for MenLooks Like Guys Are More Prone to Pack on the 'Freshman 15'New Urine Test Might Show Whether Prostate Cancer Needs TreatmentMany Young Men Putting Health at Risk to Bulk UpSperm Seems to Survive Just Fine in Space, Study Shows5 Ways Men Can Take Charge of Their HealthFitness in Middle Age Cuts Men's Odds for COPD LaterHelp for Impotence Starts With Frank Talk With DoctorYogurt Might Help Men Avoid Colon Cancer: StudyBest Gift From Dad for Kids: More Time Together'Daddy-Do-Overs': Men Increasingly Getting Plastic SurgeryMale Victims of Domestic Violence Often Suffer in Silence'Dad Shaming' Is Real, Survey ShowsFew Prostate Cancer Patients Are Getting Checkups They NeedTesticular Cancer Treatment Unlikely to Trigger Birth DefectsCould 2 Prostate Cancer Drugs Fight Disease in Earlier Stages?Many Middle-Aged Men May Have Signs of Thinning Bones'Watchful Waiting' Less Likely for Black Prostate Cancer PatientsOlder Dads' Sperm Isn't What It Used to BeMustaches Are More Than Just Manly, They Guard Against Sun's RaysHeavy Teen Boys May Face Higher Heart Disease Risk as AdultsAHA News: Study Finds Higher Risk of Stroke-Linked Plaque in Men, Possible Test for WomenIs That Prostate Cancer Worth Treating? Chromosomes May TellUse of Meds for Enlarged Prostate Might Delay a Cancer Diagnosis
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Wellness and Personal Development
Mental Disorders

Use of Meds for Enlarged Prostate Might Delay a Cancer Diagnosis

HealthDay News
by -- E.J. Mundell
Updated: May 6th 2019

new article illustration

MONDAY, May 6, 2019 (HealthDay News) -- Men who take medicines for an enlarged prostate can have years-long delays in their diagnosis of prostate cancer and more advanced prostate cancer when they're diagnosed, a new study finds.

The reason? Drugs in this class -- such as Proscar (finasteride) and Avodart (dutasteride) -- can drive down blood levels of prostate-specific antigen (PSA). That's the blood marker doctors periodically check for as they monitor men for prostate cancer.

But if physicians fail to account for this drug-induced lowering of PSA, they might conclude that it is not rising to potentially alarming levels -- and thereby miss early-stage cancers, the researchers explained.

That's what appeared to happen often among patients enrolled in the new study, according to researchers at the University of California, San Diego (UCSD).

The investigators tracked data from nearly 81,000 men who were diagnosed with prostate cancer after doctors detected elevated PSA.

The researchers saw distinct differences in outcomes for men who had taken a drug from the "5-ARI" class of medicines, such as Proscar or Avodart, versus men who hadn't. Men taking a 5-ARI drug to treat an enlarged prostate were diagnosed with prostate cancer an average of 3.6 years after their first signs of elevated PSA, compared with 1.4 years for men who did not use the drugs, the findings showed.

That means more cancers detected later in their progression, the study authors explained.

"Our data suggest that PSA suppression in this population was not routinely accounted for during screening for prostate cancer, and that this led to delays in diagnosis," said study lead author Reith Sarkar.

A delayed diagnosis can then easily result in "advanced disease and worsened clinical outcomes" for patients, Sarkar explained in a university news release. He is a clinical research associate at UCSD's department of radiation medicine and applied sciences.

The study also found that only 29% of 5-ARI users had a prostate biopsy within two years of their first elevated levels of PSA, compared with 59% of those who didn't take the drugs.

All of this may have led to another finding: That high-grade prostate cancers -- those that grow and spread quickly and have a worse prognosis -- were diagnosed in 25% of 5-ARI users, compared with 17% of those who didn't take the drugs, the team reported.

Some of these cancers proved to be metastatic. Prostate cancers that had already spread to other areas of the body were found in 7% of 5-ARI users, compared with 3% of non-users, the researchers said.

According to study senior author Dr. Brent Rose, the findings show how crucial it is "to raise awareness among medical care teams and patients that [these drugs] can cause PSA suppression."

He believes clear guidelines are needed to help bring better care to the many men prescribed these medications. Rose is assistant professor of radiation medicine and applied sciences at UCSD.

Prior research has shown that treatment with 5-ARIs can trigger about a 50% drop in levels of PSA, a protein produced by the prostate gland, the researchers noted.

Sarkar said that none of this means that men should abandon PSA testing.

"PSA screening continues to be an effective tool for prostate cancer detection among men using 5-ARIs, as long as PSA levels are adjusted for PSA suppression that occurs while taking these drugs," he said.

Two urologists who care for men with prostate issues agreed that there needs to be heightened awareness among physicians.

"Often patients will be told that their PSA levels are normal, when in fact -- because the medication causes the PSA to be half of its true level -- these patients have an elevated PSA level and need further evaluation," said Dr. Manish Vira. He's vice chair for urologic research at Northwell Health's Arthur Smith Institute for Urology, in Lake Success, N.Y.

Vira stressed that the results do not mean that drugs like Avodart or Proscar cause advanced prostate cancer; merely that their use can hamper efforts at early detection.

Dr. Elizabeth Kavaler is a urologist at Lenox Hill Hospital in New York City. She agreed that "the take-home message is that men who are on 5-ARIs for an enlarged prostate have to be monitored closely for prostate cancer, and the threshold for biopsy [for these patients] needs to be lowered."

The study was published online May 6 in JAMA Internal Medicine.

More information

The U.S. National Cancer Institute has more on prostate cancer.